Cyclic AMP-Dependent Protein Kinase as a Part of the Possible Down-regulating Pathway in the Antigen Receptor-Regulated Cytotoxic T Lymphocyte Conjugate Formation and Granule Exocytosis-Reference-Cited by-同舟云学术

Cyclic AMP-Dependent Protein Kinase as a Part of the Possible Down-regulating Pathway in the Antigen Receptor-Regulated Cytotoxic T Lymphocyte Conjugate Formation and Granule Exocytosis

Published:1988-08 Issue:1 Cytotoxic T C Volume:532 Page:350-358
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Ann NY Acad Sci

Author:

SITKOVSKY MICHAIL V.,TRENN GUIDO,TAKAYAMA HAJIME

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1749-6632.1988.tb36352.x/fullpdf

Reference15 articles.

1. Antigen-receptor interaction requirement for conjugate formation and lethal-hit triggering by cytotoxic T lymphocytes can be bypassed by protein kinase C activators and Ca2+ ionophores.

2. Serine esterase in cytolytic T lymphocytes

3. The antigen-specific, major histocompatibility complex-restricted receptor on T cells. VI. An antibody to a receptor allotype.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy;Frontiers in Immunology;2020-09-29

2. Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy;Journal of Clinical Investigation;2020-09-28

3. Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy;Current Opinion in Pharmacology;2020-08

4. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases;Nature Reviews Rheumatology;2016-11-10

5. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer;Current Opinion in Pharmacology;2016-08